Does the media prefer IDYA or CYRX?

In the previous week, CryoPort had 1 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 6 mentions for CryoPort and 5 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 1.01 beat CryoPort's score of 0.75 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, CYRX or BEAM?

CryoPort has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $176.18M 4.40 $78.30M $1.35 11.39 Beam Therapeutics $164.01M 15.74 -$79.99M -$0.68 N/A

Does the media favor CYRX or BEAM?

In the previous week, Beam Therapeutics had 1 more articles in the media than CryoPort. MarketBeat recorded 7 mentions for Beam Therapeutics and 6 mentions for CryoPort. Beam Therapeutics' average media sentiment score of 0.91 beat CryoPort's score of 0.75 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RARE or CYRX?

In the previous week, Ultragenyx Pharmaceutical had 1 more articles in the media than CryoPort. MarketBeat recorded 7 mentions for Ultragenyx Pharmaceutical and 6 mentions for CryoPort. Ultragenyx Pharmaceutical's average media sentiment score of 0.90 beat CryoPort's score of 0.75 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELVN or CYRX?

In the previous week, Enliven Therapeutics had 6 more articles in the media than CryoPort. MarketBeat recorded 12 mentions for Enliven Therapeutics and 6 mentions for CryoPort. Enliven Therapeutics' average media sentiment score of 1.07 beat CryoPort's score of 0.75 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CYRX or VERA?

In the previous week, CryoPort had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 6 mentions for CryoPort and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.78 beat CryoPort's score of 0.75 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

CryoPort (CYRX) Competitors

$15.37 -0.66 (-4.12%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$15.37 0.00 (0.00%)

As of 07/24/2026 07:34 PM Eastern

Compare

CYRX vs. IDYA, BEAM, RARE, ELVN, and VERA

Should you buy CryoPort stock or one of its competitors? MarketBeat compares CryoPort with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CryoPort include IDEAYA Biosciences (IDYA), Beam Therapeutics (BEAM), Ultragenyx Pharmaceutical (RARE), Enliven Therapeutics (ELVN), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry.

How does CryoPort compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and CryoPort (NASDAQ:CYRX) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 9.5% of CryoPort shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CryoPort has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$225.27M	13.81	-$113.70M	-$1.60	N/A
CryoPort	$176.18M	4.40	$78.30M	$1.35	11.39

In the previous week, CryoPort had 1 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 6 mentions for CryoPort and 5 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 1.01 beat CryoPort's score of 0.75 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort has a net margin of 41.57% compared to IDEAYA Biosciences' net margin of 0.00%. CryoPort's return on equity of -7.92% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
CryoPort	41.57%	-7.92%	-4.79%

IDEAYA Biosciences currently has a consensus target price of $50.25, suggesting a potential upside of 41.95%. CryoPort has a consensus target price of $16.38, suggesting a potential upside of 6.54%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe IDEAYA Biosciences is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

IDEAYA Biosciences has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market.

Summary

CryoPort beats IDEAYA Biosciences on 9 of the 16 factors compared between the two stocks.

How does CryoPort compare to Beam Therapeutics?

CryoPort (NASDAQ:CYRX) and Beam Therapeutics (NASDAQ:BEAM) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

CryoPort has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market.

In the previous week, Beam Therapeutics had 1 more articles in the media than CryoPort. MarketBeat recorded 7 mentions for Beam Therapeutics and 6 mentions for CryoPort. Beam Therapeutics' average media sentiment score of 0.91 beat CryoPort's score of 0.75 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort presently has a consensus target price of $16.38, indicating a potential upside of 6.54%. Beam Therapeutics has a consensus target price of $46.85, indicating a potential upside of 86.64%. Given Beam Therapeutics' higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

CryoPort has a net margin of 41.57% compared to Beam Therapeutics' net margin of -39.66%. CryoPort's return on equity of -7.92% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

CryoPort has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.40	$78.30M	$1.35	11.39
Beam Therapeutics	$164.01M	15.74	-$79.99M	-$0.68	N/A

92.9% of CryoPort shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 9.5% of CryoPort shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

CryoPort beats Beam Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CryoPort compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and CryoPort (NASDAQ:CYRX) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

CryoPort has a net margin of 41.57% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. CryoPort's return on equity of -7.92% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
CryoPort	41.57%	-7.92%	-4.79%

Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

CryoPort has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.94	-$575M	-$6.11	N/A
CryoPort	$176.18M	4.40	$78.30M	$1.35	11.39

Ultragenyx Pharmaceutical presently has a consensus price target of $58.41, indicating a potential upside of 117.14%. CryoPort has a consensus price target of $16.38, indicating a potential upside of 6.54%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, research analysts plainly believe Ultragenyx Pharmaceutical is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 9.5% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Ultragenyx Pharmaceutical had 1 more articles in the media than CryoPort. MarketBeat recorded 7 mentions for Ultragenyx Pharmaceutical and 6 mentions for CryoPort. Ultragenyx Pharmaceutical's average media sentiment score of 0.90 beat CryoPort's score of 0.75 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CryoPort beats Ultragenyx Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does CryoPort compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and CryoPort (NASDAQ:CYRX) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Enliven Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 9.5% of CryoPort shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Enliven Therapeutics had 6 more articles in the media than CryoPort. MarketBeat recorded 12 mentions for Enliven Therapeutics and 6 mentions for CryoPort. Enliven Therapeutics' average media sentiment score of 1.07 beat CryoPort's score of 0.75 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort has a net margin of 41.57% compared to Enliven Therapeutics' net margin of 0.00%. CryoPort's return on equity of -7.92% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
CryoPort	41.57%	-7.92%	-4.79%

Enliven Therapeutics currently has a consensus target price of $70.50, indicating a potential upside of 33.14%. CryoPort has a consensus target price of $16.38, indicating a potential upside of 6.54%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enliven Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

CryoPort has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
CryoPort	$176.18M	4.40	$78.30M	$1.35	11.39

Summary

CryoPort beats Enliven Therapeutics on 10 of the 16 factors compared between the two stocks.

How does CryoPort compare to Vera Therapeutics?

CryoPort (NASDAQ:CYRX) and Vera Therapeutics (NASDAQ:VERA) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

CryoPort has a net margin of 41.57% compared to Vera Therapeutics' net margin of 0.00%. CryoPort's return on equity of -7.92% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Vera Therapeutics	N/A	-74.86%	-60.18%

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 9.5% of CryoPort shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CryoPort has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.40	$78.30M	$1.35	11.39
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

CryoPort has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

In the previous week, CryoPort had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 6 mentions for CryoPort and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.78 beat CryoPort's score of 0.75 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CryoPort presently has a consensus target price of $16.38, suggesting a potential upside of 6.54%. Vera Therapeutics has a consensus target price of $84.58, suggesting a potential upside of 138.60%. Given Vera Therapeutics' higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

CryoPort beats Vera Therapeutics on 10 of the 15 factors compared between the two stocks.

Get CryoPort News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYRX vs. The Competition

Export

Metric	CryoPort	TRANS Industry	Transportation Sector	NASDAQ Exchange
Market Cap	$807.95M	$7.32B	$8.91B	$12.26B
Dividend Yield	N/A	2.50%	973.95%	9.79%
P/E Ratio	11.39	31.28	24.22	23.71
Price / Sales	4.40	2.52	5.36	76.09
Price / Cash	N/A	9.86	8.52	59.64
Price / Book	1.67	2.45	2.30	6.07
Net Income	$78.30M	$243.42M	$532.19M	$331.84M
7 Day Performance	-6.90%	0.56%	2.38%	-1.53%
1 Month Performance	-3.21%	1.97%	0.66%	-2.46%
1 Year Performance	95.80%	-8.22%	26.43%	13.66%

CryoPort Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYRX CryoPort	2.948 of 5 stars	$15.37 -4.1%	$16.38 +6.5%	+92.6%	$807.95M	$176.18M	11.39	1,186	News Coverage Analyst Forecast Gap Up
IDYA IDEAYA Biosciences	3.8572 of 5 stars	$36.74 +0.2%	$50.25 +36.8%	+42.6%	$3.22B	$218.71M	N/A	80	Positive News
BEAM Beam Therapeutics	2.5385 of 5 stars	$30.84 -0.2%	$46.85 +51.9%	+19.8%	$3.18B	$164.01M	N/A	510	News Coverage Positive News
RARE Ultragenyx Pharmaceutical	3.8535 of 5 stars	$31.71 -1.0%	$58.41 +84.2%	-1.5%	$3.15B	$673M	N/A	1,371	News Coverage Options Volume
ELVN Enliven Therapeutics	3.0792 of 5 stars	$53.16 +2.8%	$69.17 +30.1%	+141.2%	$3.15B	N/A	N/A	50	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYRX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CryoPort (CYRX) Competitors

CYRX vs. IDYA, BEAM, RARE, ELVN, and VERA

How does CryoPort compare to IDEAYA Biosciences?

Summary

How does CryoPort compare to Beam Therapeutics?

Summary

How does CryoPort compare to Ultragenyx Pharmaceutical?

Summary

How does CryoPort compare to Enliven Therapeutics?

Summary

How does CryoPort compare to Vera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX vs. The Competition

CryoPort Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CryoPort (CYRX) Competitors

CYRX vs. IDYA, BEAM, RARE, ELVN, and VERA

How does CryoPort compare to IDEAYA Biosciences?

Do institutionals & insiders hold more shares of IDYA or CYRX?

Which has higher earnings and valuation, IDYA or CYRX?

Does the media prefer IDYA or CYRX?

Is IDYA or CYRX more profitable?

Do analysts rate IDYA or CYRX?

Which has more risk and volatility, IDYA or CYRX?

Summary

How does CryoPort compare to Beam Therapeutics?

Which has more risk and volatility, CYRX or BEAM?

Does the media favor CYRX or BEAM?

Do analysts recommend CYRX or BEAM?

Is CYRX or BEAM more profitable?

Which has stronger valuation and earnings, CYRX or BEAM?

Do institutionals & insiders have more ownership in CYRX or BEAM?

Summary

How does CryoPort compare to Ultragenyx Pharmaceutical?

Is RARE or CYRX more profitable?

Which has more volatility and risk, RARE or CYRX?

Which has preferable valuation and earnings, RARE or CYRX?

Do analysts recommend RARE or CYRX?

Do institutionals and insiders believe in RARE or CYRX?

Does the media prefer RARE or CYRX?

Summary

How does CryoPort compare to Enliven Therapeutics?

Which has more volatility & risk, ELVN or CYRX?

Do institutionals & insiders believe in ELVN or CYRX?

Does the media prefer ELVN or CYRX?

Is ELVN or CYRX more profitable?

Do analysts recommend ELVN or CYRX?

Which has better earnings & valuation, ELVN or CYRX?

Summary

How does CryoPort compare to Vera Therapeutics?

Is CYRX or VERA more profitable?

Do institutionals and insiders hold more shares of CYRX or VERA?

Which has preferable earnings and valuation, CYRX or VERA?

Which has more volatility & risk, CYRX or VERA?

Does the media favor CYRX or VERA?

Do analysts rate CYRX or VERA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX vs. The Competition

CryoPort Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools